NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (AMEX: PRW), a developer of first-in-class, carbohydrate-based targeted therapeutic compounds to treat cancer and liver fibrosis, has retained the Investor Relations Group, Inc. (“IRG”), based in New York City, to serve as its financial relations and corporate communications firm.
